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(57) ABSTRACT 
Provided are methods and compositions for the treatment or 
prevention of ocular angiogenesis and neovascularization. 
Administration of inhibitors of the CCR3 receptor or its 
ligands eotaxin (CCLII), eotaxin-2 (CCL24) or eotaxin-3 
(CCL26) inhibits ocular angiogenesis. 
11 Claims, 5 Drawing Sheets 
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CCR3 INHIBITION FOR OCULAR 
ANGIOGENESIS AND MACULAR 
DEGENERATION 
FIELD OF THE INVENTION 
The present invention relates to the suppression of ocular 
angiogenesis by inhibiting the CCR3 receptor. 
DESCRIPTION OF THE RELATED ART 
2 
FIG. 5 illustrates the lack of change of number of infil-
trating macrophages in the choroid following laser injury 
and CCR3 antibody treatment. 
DESCRIPTION OF PREFERRED 
EMBODIMENTS 
Intraocular inflanmiation is not clinically apparent in 
age-related macular degeneration. However, there is evi-
10 dence suggesting an influential role for inflanmiation in this 
condition. CCR3 is a promiscuous chemokine receptor that 
is predominantly expressed by eosinophils but also is found 
on other leukocytes and some endothelial and epithelial 
cells. 
The macula is the part of the retina which is responsible 
for central vision. Age-related macular degeneration is a 
chronic eye disease that occurs when tissue in the macula 
deteriorates. Macular affects central vision, but not periph- 15 
era! vision. Macular degeneration is the leading cause of 
severe vision loss in people age 60 and older. 
The invention relates to methods and compositions for the 
treatment or prevention of ocular angiogenesis and neovas-
cularization. Administration of inhibitors of the CCR3 
receptor or its ligands, for example eotaxin (CCLI 1 ), 
eotaxin-2 (CCL24) or eotaxin-3 (CCL26), inhibits ocular 
angiogenesis. Ocular angiogenesis includes choroidal angio-
genesis and retinal angiogenesis. Compositions and methods 
There are two forms of age-related macular degeneration: 
dry and wet. Dry macular degeneration is the most common 
type of macular degeneration and occurs when cells of the 20 
macula slowly begin to break down. Yellow deposits called 
"drusen" form under the retina between the retinal pig-
mented epithelium (RPE) and Bruch's membrane, which 
supports the retina. The drusen deposits are debris associated 
with compromised cell metabolism in the RPE. Eventually 25 
there is a deterioration of the macular regions associated 
with the drusen deposits resulting in a loss of central vision. 
for inhibiting CCR3, eotaxin (CCLII), eotaxin-2 (CCL24), 
and eotaxin-3 (CCL26) for the treatment and/or prevention 
of neovascular disease are provided. Also provided are novel 
therapeutic targets and diagnostic markers for choroidal 
neovascularization. 
Any compound which inhibits the activity of CCR3 may 
be used in the present invention. Such compounds include 
inhibitory molecules which bind directly to the CCR3 recep-
tor, antibodies which bind the CCR3 receptor or to the 
natural ligands of the CCR3 receptor, including eotaxin 
Wet macular degeneration occurs when abnormal bold 
vessels grow behind the macula. These vessels are fragile 
and can leak fluid and blood, which result in scarring of the 30 
macula and raise the potential for rapid, severe damage. 
Bruch's membrane breaks down, usually near drusen depos- (CCLII), eotaxin-2 (CCL24) and eotaxin-3 (CCL26), RNA, 
DNA or RNA/DNA aptamers which specifically bind CCR3, 
eotaxin, eotaxin-2 or eotaxin-3, and siRNA or anti-sense 
oligonucleotides which inhibit the expression of CCR3, 
eotaxin, eotaxin-2 or eotaxin-3. 
its. This is where new blood vessel growth, or neovascular-
ization, occurs. Central vision can become distorted or lost 
entirely in a shore period of time, sometimes within days. 35 
Wet macular degeneration is responsible for about 10 per-
cent of the cases of age-related macular degeneration, but it 
accounts for about 90 percent of the cases oflegal blindness. 
Numerous "small molecule" inhibitors for the CCR3 
receptor have been developed and can be used in the present 
invention. In one aspect the CCR3 inhibitor is an organic 
SUMMARY OF THE INVENTION 
The present invention relates to a method of inhibiting 
ocular angiogenesis. The method comprises exposing a 
choroidal cell to a CCR3-inhibitory effective amount of a 
compound which inhibits the activity ofCCR3. The present 
invention also relates to a composition for the inhibition of 
ocular angiogenesis. The composition comprises a com-
pound which inhibits the activity of CCR3. 
Other systems, methods, features and advantages of the 
present invention will be or become apparent to one with 
skill in the art upon examination of the following drawings 
and detailed description. It is intended that all such addi-
tional systems, methods, features and advantages be 
included within this description, be within the scope of the 
present invention, and be protected by the accompanying 
claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 illustrates the effect of laser injury on the number 
of CCR3 receptors on choroidal endothelial cells. 
FIG. 2 shows the effect of CCR3 antibody on the prolif-
eration of choroidal endothelial cells following laser injury. 
FIG. 3 illustrates the dose-dependent effect of CCR3 
antibody on choroidal neovascularization volume 
FIG. 4 shows lack of infiltration of eosinophils and mast 
cells into the choroid following laser injury. 
40 molecule having a molecular weight less than 1000. In 
another aspect of the invention, the CCR3 inhibitor is an 
organic molecule having a molecular weight less than 500. 
The CCR3 receptor inhibitors include piperidine derivatives, 
piperidine amides and piperidine compounds such as those 
45 described in U.S. Pat. Nos. 6,984,651 and 6,903,115, and 
U.S. published applications 20050176708, 20050182094 
and 20050182095; heterocyclic piperidines such as those 
described in U.S. Pat. No. 6,759,411; diphenyl-piperidine 
derivatives such as those described in U.S. Pat. No. 6,566, 
50 376; 2,5-substituted pyrimidine derivatives such as those 
described in U.S. Pat. No. 6,984,643; piperizinones such as 
those described in U.S. Pat. No. 6,974,869; bicycylic and 
tricyclic amines such as those described in U.S. Pat. No. 
6,960,666; N-ureidoalkyl-piperidines such as those 
55 described in U.S. Pat. Nos. 6,949,546, 6,919,368, 6,906,066, 
6,897,234, 6,875,776, 6,780,857, 6,627,629, 6,521,592 and 
6,331,541; bicyclic diamines such as those described in U.S. 
Pat. No. 6,821,964; benzylcycloalkyl amines such as those 
described in U.S. Pat. No. 6,864,380; 2-substituted-4-nitro-
60 gen heterocycles such as those described in U.S. Pat. No. 
6,706,735; ureido derivatives of poly-4-amino-2-carboxy-l-
methylpyrrole compounds; bicyclic and bridged nitrogen 
heterocycles such as those described in U.S. published 
application 20050234034; azetidine derivatives such as 
65 those described in U.S. published application 20050222118; 
substituted fused bicyclic amines such as those described in 
U.S. published application 20050197373; substituted spiro 
US 10,344,095 B2 
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azabicyclics such as those described in U.S. published 
application 20050197325; piperidine-substituted indoles or 
heteroderivatives thereof such as those described in U.S. 
published application 20050153979; piperidinyl and piper-
azinyl compounds substituted with bicyclo-heterocyclylal- 5 
kyl groups such as those described in U.S. published appli-
cation 20050090504; arylsulfonamide derivatives such as 
those described in U.S. published application 20050070582; 
l-phenyl-1,2-diaminoethane derivatives such as those 
described in U.S. published application 20040063779; (N-{ 10 
[2S]-4-(3,4-dichlorobenzyl)morpholin-2-yl}methyl)-N'[(2-
methyl-2H-tetraazol-5-yl)methyl]urea) (see, e.g., Nakamura 
et al., Immunol Res., 33:213-222, 2006; N-{(3R)-1-[(6-
fluoro-2-naphthyl)methyl]pyrrolidin-3-yl }-2-{ 1-[ (3-
methyl-1-oxidopyridin-2-yl)carbonyl]piperidin-4- 15 
ylidene}acetamide (see, e.g., Suzuki et al., Biochem. 
Biophys. Res. Commun., 339:1217-1223, 2006; N-{(3R)-1-
[ ( 6-fluoro-2-naphthyl)methyl]pyrrolidin-3-yl }-2-{ 1-[ (5-hy-
droxy-3-methylpyridin-2-yl)carbonyl]piperidin-4-
ylidene}acetamide hemifumarate (see, e.g., Morokata et al., 20 
J. Pharmacol. Exp. Ther., Dec. 9, 2005 [Epub ahead of 
print]); bipiperidine amide antagonists of CCR3 such as 
those described in Ting et al., Bioorg. Med. Chem. Lett., 
15:3020-3023, 2005; (S)-methyl-2-naphthoylamino-3-( 4-ni-
trophenyl)propionate (see, e.g., Beasley et al., J. Allergy 25 
Clin. Immunol., 105: S466-S472, 2000; and the CCR3 
antagonist compounds described in Fryer et al., J. Clin. 
Invest., 116:228-236, 2006. 
Additional compounds for inhibiting the CCR3 receptor 
include RNA, DNA or RNA/DNA aptamers directed against 30 
CCR3, eotaxin, eotaxin-2 or eotaxin-3. Exemplary methods 
for making aptamers are described in U.S. Pat. Nos. 5,270, 
163, 5,840,867, 6,180,348 and 6,699,843. 
Additional compounds for inhibiting the CCR3 receptor 
include anti-sense oligonucleotides or siRNAs directed 35 
against CCR3, eotaxin, eotaxin-2 or eotaxin-3, including the 
anti-sense oligonucleotides directed against the CCR3 
receptor such as that described in U.S. Pat. No. 6,822,087. 
The siRNAs for use in the present invention are designed 
according to standard methods in the field of RNA interfer- 40 
ence. Introduction of siRNAs into cells may be by transfec-
tion with expression vectors, by transfection with synthetic 
dsRNA, or by any other appropriate method. Transfection 
with expression vectors is preferred. 
The expression vectors which can be used to deliver 45 
siRNA according to the invention include retroviral, adeno-
viral and lentiviral vectors. The expression vector includes a 
sequence which codes for a portion of the target gene ( e.g., 
CCR3 receptor, eotaxin, eotaxin-2 or eotaxin-3) which is to 
be silenced. The target gene sequence is designed such that, 50 
upon transcription in the transfected host, the target RNA 
sequence forms a hairpin structure due to the presence of 
self-complementary bases. Processing within the cell 
removes the loop resulting in formation of a siRNA duplex. 
The double stranded RNA sequence should be less than 30 55 
nucleotide bases; preferably the dsRNA sequence is 19-25 
bases in length; more preferably the dsRNA sequence is 20 
nucleotides in length. 
The expression vectors may include one or more promoter 
regions to enhance synthesis of the target gene sequence. 60 
Promoters which can be used include CMV promoter, SV 40 
promoter, promoter of mouse U6 gene, and promoter of 
human Hl gene. 
One or more selection markers may be included to 
facilitate transfection with the expression vector. The selec- 65 
tion marker may be included within the expression vector, or 
may be introduced on a separate genetic element. For 
4 
example, the bacterial hygromycin B phosphotransferase 
gene may be used as a selection marker, with cells being 
grown in the presence ofhygromycin to select for those cells 
transfected with the aforementioned gene. 
Synthetic dsRNA may also be introduced into cells to 
provide gene silencing by siRNA. The synthetic dsRNAs are 
less than 30 base pairs in length. Preferably the synthetic 
dsRNAs are 19-25 base pairs in length. More preferably the 
dsRNAs are 19, 20 or 21 base pairs in length, optionally with 
2-nucleotide 3' overhangs. The 3' overhangs are preferably 
TT residues. 
Synthetic dsRNAs can be introduced into cells by injec-
tion, by complexing with agents such as cationic lipids, by 
use of a gene gun, or by any other appropriate method. 
Additional compounds for inhibiting the CCR3 receptor 
include antibodies which specifically bind the CCR3 recep-
tor, eotaxin, eotaxin-2 or eotaxin-3. Exemplary antibodies 
which specifically bind and inhibit the CCR3 receptor are 
described in U.S. Pat. Nos. 6,806,061 and 6,207,155, and in 
U.S. published applications 20050191702, 20050069955, 
and 20020147312. Exemplary antibodies which specifically 
bind and inhibit eotaxin and eotaxin-2 are described in U.S. 
Pat. Nos. 6,946,546 and 6,635,251, and in U.S. published 
applications 20040191255 and 20040014132. 
The antibodies of the present invention can be polyclonal 
or monoclonal, and the term antibody is intended to encom-
pass both polyclonal and monoclonal antibodies. Antibodies 
of the present invention can be raised against an appropriate 
immunogen, including proteins or polypeptides of the pres-
ent invention, such as isolated and/or recombinant mamma-
lian CCR3 receptor, eotaxin, eotaxin-2 or eotaxin-3 protein 
or portion thereof, or synthetic molecules, such as synthetic 
peptides. 
Preparation of immunizing antigen, and polyclonal and 
monoclonal antibody production can be performed using 
any suitable technique. A variety of methods have been 
described (see e.g., Kohler et al., Nature, 256: 495-497 
(1975) and Eur. J. Immunol. 6: 511-519 (1976); Milstein et 
al., Nature 266: 550-552 (1977); Koprowski et al., U.S. Pat. 
No. 4,172,124; Harlow, E. and D. Lane, 1988, Antibodies: A 
Laboratory Manual, (Cold Spring Harbor Laboratory Cold 
Spring Harbor, N.Y.); Current Protocols In Molecular Biol-
ogy, Vol. 2 (Supplement 27, Summer '94), Ausubel, F. M. et 
al., Eds., (John Wiley & Sons: New York, N.Y.), Chapter 11, 
(1991)). Generally, a hybridoma is produced by fusing a 
suitable immortal cell line ( e.g., a myeloma cell line such as 
SP2/0) with antibody producing cells. The antibody produc-
ing cell, preferably those of the spleen or lymph nodes, are 
obtained from animals immunized with the antigen of inter-
est. The fused cells (hybridomas) are isolated using selective 
culture conditions, and cloned by limiting dilution. Cells 
which produce antibodies with the desired specificity are 
selected by a suitable assay (e.g., ELISA). 
Single chain antibodies, and chimeric, humanized or. 
primatized (CDR-grafted) antibodies, as well as chimeric or 
CDR-grafted single chain antibodies, comprising portions 
derived from different species, are also encompassed by the 
present invention and the term "antibody". The various 
portions of these antibodies can be joined together chemi-
cally by conventional techniques, or can be prepared as a 
contiguous protein using genetic engineering techniques. 
For example, nucleic acids encoding a chimeric or human-
ized chain can be expressed to produce a contiguous protein. 
See, e.g., Cabilly et al., U.S. Pat. No. 4,816,567; Cabilly et 
al., European Patent No. 0,125,023. Bl; Boss et al., U.S. Pat. 
No. 4,816,397; Boss et al., European Patent No. 0,120,694 
Bl; Neuberger, M. S. et al., WO 86/01533; Neuberger, M. S. 
US 10,344,095 B2 
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et al., European Patent No. 0,194,276 Bl; Winter, U.S. Pat. 
No. 5,225,539; and Winter, European Patent No. 0,239,400 
Bl. See also, Newman, R. et al., BioTeclmology, 10: 1455-
1460 (1992), regarding primatized antibody, and Ladner et 
al., U.S. Pat. No. 4,946,778 and Bird, R. E. et al., Science, 
242: 423-426 (1988)) regarding single chain antibodies. 
In addition, functional fragments of antibodies, including 
fragments of chimeric, humanized, primatized or single 
chain antibodies, can also be produced. Functional frag-
ments of foregoing antibodies retain at least one binding 
function and/or modulation function of the full-length anti-
body from which they are derived. For example, antibody 
fragments capable of binding to a mammalian CCR3 recep-
tor, eotaxin, eotaxin-2 or eotaxin-3 or portion thereof, 
including, but not limited to, Fv, Fab, Fab' and F(ab').sub.2 
fragments are encompassed by the invention. Such frag-
ments can be produced by enzymatic cleavage or by recom-
binant teclmiques. For instance, papain or pepsin cleavage 
can generate Fab or F(ab').sub.2 fragments, respectively. 
Alternatively, antibodies can be produced in a variety of 
truncated forms using antibody genes in which one or more 
stop codons has been introduced upstream of the natural stop 
site. For example, a chimeric gene encoding a F(ab').sub.2 
heavy chain portion can be designed to include DNA 
sequences encoding the CH.sub.I domain and hinge region 
of the heavy chain. 
The antibodies of the present invention can be used to 
modulate receptor or ligand function in research and thera-
peutic applications. For instance, antibodies can act as 
inhibitors to inhibit (reduce or prevent) (a) binding (e.g., of 
a ligand, a second inhibitor or a promoter) to the receptor, (b) 
6 
pig, goat, horse, mouse, rat, dog, cat, rabbit, guinea pig, 
hamster and horse. Humans are preferred. 
According to the method of the invention, one or more 
compounds can be administered to the host by an appropri-
5 ate route, either alone or in combination with another drug. 
An effective amount of a compound ( e.g., a small molecule 
CCR3 receptor antagonist which inhibits ligand binding, an 
antibody or an siRNA) is administered. An effective amount 
is an amount sufficient to achieve the desired therapeutic 
10 effect, under the conditions of administration, such as an 
amount sufficient for inhibition of a CCR3 receptor function, 
and thereby inhibition of ocular angiogenesis. 
A variety of routes of administration are possible includ-
ing, but not necessarily limited to oral, dietary, topical, 
15 parenteral ( e.g., intravenous, intraarterial, intramuscular, 
subcutaneous injection), inhalation ( e.g., intrabronchial, 
intranasal or oral inhalation, intranasal drops), and intraocu-
lar injection routes of administration, depending on the 
disease or condition to be treated. Intraocular injection 
20 routes include periocular (subconjunctival/transscleral), 
intravitreous, subretinal and intracameral modes of injec-
tion. 
Formulation of a compound to be administered will vary 
according to the route of administration selected (e.g., 
25 solution, emulsion, capsule). An appropriate composition 
comprising the compound to be administered can be pre-
pared in a physiologically acceptable vehicle or carrier. For 
solutions or emulsions, suitable carriers include, for 
example, aqueous or alcoholic/aqueous solutions, emulsions 
30 or suspensions, including saline and buffered media. Paren-
teral vehicles can include sodium chloride solution, Ringer's 
dextrose, dextrose and sodium chloride, lactated Ringer's or 
fixed oils. Intravenous vehicles can include various addi-a receptor signalling, ( c) and/or a stimulatory function. 
Antibodies which act as inhibitors of receptor function can 
block ligand or promoter binding directly or indirectly ( e.g., 35 
by causing a conformational change). For example, antibod-
tives, preservatives, or fluid, nutrient or electrolyte replen-
ishers (See, generally, Remington's Pharmaceutical Science, 
16th Edition, Mack, Ed. 1980). For inhalation, the com-
ies can inhibit receptor function by inhibiting binding of a 
ligand, or by desensitization (with or without inhibition of 
binding of a ligand). 
Anti-idiotypic antibodies. are also provided. Anti-idio- 40 
typic antibodies recognize antigenic determinants associated 
with the antigen-binding site of another antibody. Anti-
idiotypic antibodies can be prepared against a second anti-
body by immunizing an animal of the same species, and 
preferably of the same strain, as the animal used to produce 45 
the second antibody. See e.g., U.S. Pat. No. 4,699,880. 
Single chain, and chimeric, humanized or primatized (CDR-
grafted), as well as chimeric or CDR-grafted single chain 
anti-idiotypic antibodies can be prepared, and are encom-
passed by the term anti-idiotypic antibody. Antibody frag- 50 
ments of such antibodies can also be prepared. 
Modulation of mammalian CCR3 receptor function 
according to the present invention, through the inhibition of 
pound is solubilized and loaded into a suitable dispenser for 
administration (e.g., an atomizer, nebulizer or pressurized 
aerosol dispenser). 
EXAMPLE 1 
Methods 
Laser photocoagulation (532 nm, 200 mW, 100 ms, 75 
µm) (OCULIGHT™ GL, Iridex Corporation) was per-
formed (volume studies: 3/eye; protein analyses/flow 
cytometry: 12/eye) on both eyes of each animal to induce 
CNV (choroidal neovascularization). CNV volumes were 
measured by scanning laser confocal microscope (TCS SP, 
Leica) with 0.5% FITC-Griffonia simplicifolia Isolectin B4 
(Vector Laboratories). CNV was induced by laser injury in 
C57BL/6J and Ccr-1- mice and volumes measured 7 days 
later by confocal evaluation of Griffonia simplicifolia Isolec-
tin B4 staining of RPE-choroid flatmounts. Neutralizing at least one function characteristic of a mammalian CCR3 
receptor, provides an effective and selective way of inhib-
iting ocular angiogenesis. One or more inhibitors of CCR3 
receptor function, such as those identified as described 
herein, can be used to inhibit ocular angiogenesis for thera-
peutic purposes. 
55 antibodies (Ab) against CCR3, eotaxin (CCL-11), eotaxin-2 
(CCL-24), RANTES, MCP-3 or control goat IgG or rat 
IgG2 a were injected into the vitreous humor following 
injury. 
Thus, the present invention provides a method of inhib-
iting ocular angiogenesis in an individual in need of such 
therapy, comprising administering a compound which inhib-
its mammalian CCR3 receptor function to an individual in 
need of such therapy. Such individuals include those having 
age-related macular degeneration. 
The methods of the present invention can be used in any 
mammalian species, including human, monkey, cow, sheep, 
Flow cytometry was used to determine the numbers of 
60 eosinophils, mast cells and macrophages in the choroid, 
expression of CCR3 by various cell types in the eye, and the 
cell cycle state of choroidal endothelial cells ( CE Cs) in vivo. 
Suspensions of cells isolated from mouse RPE/choroid by 
incubation with collagenase D (20 U/ml; Roche Diagnos-
65 tics) treatment were incubated in Fe block (0.5 mg/ml; BD 
Pharmingen) for 15 min on ice. Rat antibody to mouse 
CCR3 (1:250; Santa Cruz) coupled with PE-donkey anti-
US 10,344,095 B2 
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body to rat IgG (1 :250; Jackson Innnunoresearch) were used 
to quantify cell surface receptor expression on choroidal 
endothelial cells, defined by CD31 + VEGFR-Y expression, 
gated by FITC-conjugated rat antibody to mouse CD31 
(1:250; BD Biosciences) and PerCP-Cy-5.5-conjugated rat 5 
antibody to mouse CDllb (1:50; BDBiosciences). Macro-
phages, neutrophils, eosinophils and mast cells were defined 
as F4/80+CDllc-, Gr-l+F4/80-, CCR3h'CD3-
CD117'n'CD49d+ and CCR3'n'CD3- CD117h'CD49d+ cells, 
8 
These findings demonstrate that CCR3 receptor promotes 
angiogenesis not via leukocyte modulation but rather by 
direct effects on CECs. Thus, CCL-11, CCL-24, and CCR3 
are new targets for neovascular AMD (age-related macular 
degeneration). 
All references cited in this disclosure are incorporated by 
reference to the same extent as if each reference had been 
incorporated by reference in its entirety individually. 
While the invention has been described in detail and with 
respectively. DNA content for cell cycle was analyzed after 10 reference to specific embodiments thereof, it will be appar-
incubation with propidium iodide (0.05 mg/ml; Molecular ent to one skilled in the art that various variations and 
Probes) containing 0.1% TRITON™ X-100 and RNase A 
(0.1 mg/ml; Roche). 
Because the probability of each laser lesion developing 
CNV is influenced by the group to which it belongs, the 15 
mouse, the eye, and the laser spot, the mean lesion volumes 
were compared using a linear mixed model with a split plot 
repeated measures design. The whole plot factor was the 
genetic group to which the animal belonged while the split 
plot factor was the eye. Statistical significance was deter- 20 
mined at the 0.05 level. Post hoc comparison of means was 
constructed with a Bonferroni adjustment for multiple com-
modifications can be made therein without departing from 
the sprit and scope thereof. All such variations and modifi-
cations are intended to be included within the scope of this 
disclosure and the present invention and protected by the 
following claims. 
I claim: 
1. A method of inhibiting ocular angiogenesis comprising 
exposing a choroidal cell to a CCR3-inhibitory effective 
amount of an antibody which inhibits the activity of CCR3. 
2. The method of claim 1 wherein the choroidal cell is a 
choroidal endothelial cell. parisons. 
Results 
As illustrated by FIG. 1, the numberofCCR3 receptors on 
choroidal endothelial cells in vivo following laser injury 
(red) is significantly greater than the number before injury 
(green), indicating upregulation ofCCR3 receptors on these 
cells. Eosinophils or mast cells are the principal cells in most 
systems that respond to CCR3. However, the number of 
eosinophils and mast cells in the choroid was unaffected by 
injury or CCR3 Ab (FIG. 4). CCR3 Ab did not inhibit 
choroidal macrophage infiltration following injury (FIG. 5), 
indicating that laser injury is not working by anti-inflam-
matory means. As illustrated by FIG. 3, CCR3 Ab sup-
pressed CNV volume in C57BL/6J mice by nearly 60% in 
a dose-dependent and statistically significant manner com-
pared to vehicle control (PBS) and control antibody (rat 
IgG2a). FIG. 2 demonstrates that CCR3 Ab blockade, but 
not control antibody (rat IgG2a), inhibited proliferation (S 
phase) ofCECs (choroidal endothelial cells) in vivo follow-
ing laser injury. Experiments in ccr3-1- mice confirmed 
these results. Of the CCR3 ligands, blockade of only eotaxin 
(45%) or eotaxin-2 (70%) suppressed CNV in C57BL/6J 
mice compared to control antibodies (all Ps<0.001). Experi-
ments in Ccl11-1- and Ccl24-1- mice confirmed these results. 
3. The method of claim 1 wherein exposing the choroidal 
25 cell to the antibody takes place in a mannnal. 
4. The method of claim 3 wherein the antibody is orally 
administered to the mannnal. 
5. The method of claim 3 wherein the antibody is intra-
venously administered to the mannnal. 
30 6. The method of claim 3 wherein the antibody is 
intraocularly injected into the mannnal. 
7. The method of claim 1 wherein the antibody is an 
antibody or antibody fragment which specifically binds 
CCR3 and thereby inhibits the activity of CCR3. 
35 8. The method of claim 1 wherein the antibody is an 
antibody or antibody fragment which specifically binds 
eotaxin and thereby inhibits the activity of CCR3. 
9. The method of claim 1 wherein the antibody is an 
antibody or antibody fragment which specifically binds 
40 eotaxin-2 and thereby inhibits the activity of CCR3. 
10. The method of claim 1 wherein the antibody is an 
antibody or antibody fragment which specifically binds 
eotaxin-3 and thereby inhibits the activity of CCR3. 
11. The method of claim 3 wherein the mannnal is a 
45 human. 
* * * * * 
